Xyzal and alcohol. Indications for use, instructions for taking xyzal for children and adults, analogues, reviews. With nasal congestion


treatment of such symptoms of year-round (persistent) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis as itching, sneezing, nasal congestion, rhinorrhea, lacrimation, conjunctival hyperemia;

Pollinosis (hay fever).

Urticaria, incl. chronic idiopathic urticaria, angioedema;

Other allergic dermatoses, accompanied by itching and rashes.

Release form of the drug Ksizal

drops for oral administration 5 mg / ml; dark glass dropper bottle 10 ml, cardboard pack 1;

Drops for oral administration 5 mg / ml; dark glass dropper bottle 20 ml, cardboard pack 1;

Compound
Film-coated tablets 1 tab.
active substance:
excipients: MCC - 30 mg; lactose monohydrate - 63.5 mg; colloidal silicon dioxide - 0.5 mg; magnesium stearate - 1 mg
shell: Opadry Y-1-7000 (hypromellose (E464) - 62.5%; titanium dioxide (E171) - 31.25%; macrogol-400 - 6.25%) - 3 mg
in a blister pack 7 or 10 pcs.; in a pack of cardboard 1 or 2 packs.

Drops for oral administration 1 ml
active substance:
levocetirizine dihydrochloride 5 mg
excipients: sodium acetate; acetic acid; propylene glycol; glycerol 85%; methyl parahydroxybenzoate; propyl parahydroxybenzoate; sodium saccharin; purified water
dark glass dropper bottles of 10 or 20 ml; in a pack of cardboard 1 bottle.

Pharmacodynamics of the drug Xyzal

Levocetirizine, the active substance of Xyzal®, is the R-enantiomer of cetirizine, which belongs to the group of competitive histamine antagonists and blocks H1-histamine receptors. The affinity for H1-histamine receptors in levocetirizine is 2 times higher than that of cetirizine.

Levocetirizine has an effect on the histamine-dependent stage of allergic reactions, and also reduces the migration of eosinophils, reduces vascular permeability, and limits the release of inflammatory mediators and cytokines (VCAM-1, etc.).

Levocetirizine prevents the development and facilitates the course of allergic reactions, has an antiexudative, antipruritic effect, and practically does not have an anticholinergic and antiserotonin effect. In therapeutic doses, it practically does not have a sedative effect.

Pharmacokinetics of Xyzal

The pharmacokinetic parameters of levocetirizine change linearly and practically do not differ from the pharmacokinetics of cetirizine.

Suction. After oral administration, the drug is rapidly and completely absorbed from the gastrointestinal tract. Eating does not affect the completeness of absorption, although its rate decreases. In adults, after a single dose of the drug at a therapeutic dose (5 mg), Cmax in blood plasma is 270 ng / ml and is achieved after 0.9 hours, after repeated administration at a dose of 5 mg - 308 ng / ml. Css is reached in 2 days.

Distribution. Levocetirizine is 90% bound to plasma proteins. Vd is 0.4 l/kg. Bioavailability reaches 100%.

Metabolism. In small quantities (<14%) метаболизируется в организме путем N- и О-дезалкилирования (в отличие от других антагонистов Н1-гистаминовых рецепторов, которые метаболизируются в печени с помощью системы цитохромов) с образованием фармакологически неактивного метаболита. Из-за низкого уровня метаболизма и отсутствия метаболического потенциала взаимодействие левоцетиризина с другими лекарственными препаратами представляется маловероятным.

Withdrawal. In adults, T1 / 2 is (7.9 ± 1.9) h; in young children, T1 / 2 is shortened. In adults, the total clearance is 0.63 ml / min / kg. About 85.4% of the accepted dose of the drug is excreted by the kidneys unchanged by glomerular filtration and tubular secretion; about 12.9% - through the intestines.

In patients with renal insufficiency (Cl creatinine<40 мл/мин) клиренс препарата уменьшается, а T1/2 удлиняется (так, у больных, находящихся на гемодиализе, общий клиренс снижается на 80%), что требует соответствующего изменения режима дозирования. Менее 10% левоцетиризина удаляется в ходе стандартной 4-часовой процедуры гемодиализа.

Use of Xyzal during pregnancy

Experimental animal studies have not revealed any direct or indirect adverse effects of levocetirizine on the developing fetus, as well as on development in the postnatal period; the course of pregnancy and childbirth also did not change.

Adequate and strictly controlled clinical studies on the safety of the drug during pregnancy have not been conducted, so levocetirizine should not be prescribed during pregnancy.

Levocetirizine is excreted in breast milk, so its use is possible only if the expected benefit to the mother outweighs the potential risk to the child.

Contraindications to the use of Xyzal

Common to all dosage forms

Hypersensitivity to levocetirizine or piperazine derivatives, as well as to other components of the drug;

End-stage renal disease (Cl creatinine<10 мл/мин);

Pregnancy (due to the lack of data on the efficacy and safety of the drug).

With caution: chronic renal failure (correction of the dosing regimen is required); advanced age (possibly decreased glomerular filtration rate).

For film-coated tablets additionally:

Galactosemia or severe lactose intolerance;

Children's age up to 6 years.

For drops additionally:

Children under 2 years of age (due to limited data on the efficacy and safety of the drug);

Side effects of Xyzal

Possible side effects are listed below by body systems and frequency of occurrence: often (≥1/10), infrequently (≥1/100,<1/10), редко (≥1/1000, <1/100), очень редко (≥1/10000, <1/1000).

From the nervous system: infrequently - headache, fatigue, drowsiness; rarely - asthenia; very rarely - aggression, agitation, hallucinations, depression, convulsions.

From the senses: very rarely - visual impairment.

From the digestive system: infrequently - dry mouth; rarely - abdominal pain; very rarely - nausea, diarrhea, hepatitis.

From the CCC: very rarely - tachycardia.

From the respiratory system: very rarely - dyspnea.

From the musculoskeletal system: very rarely - myalgia.

From the side of metabolism: very rarely - weight gain.

On the part of laboratory parameters: very rarely - changes in liver function tests.

Allergic reactions: very rarely - itching, rash, urticaria, angioedema, anaphylaxis.

Dosing and Administration of Ksizal

Inside, during meals or on an empty stomach, with a small amount of water, without chewing. The recommended dose for adults and children over 6 years of age, elderly patients (subject to normal kidney function) is 5 mg (1 tablet). The course of treatment for polynosis is 1-6 weeks, for chronic diseases (perennial rhinitis, atopic dermatitis) - up to 18 months.

Overdose of Xyzal

Symptoms: drowsiness (in adults), agitation and anxiety, followed by drowsiness (in children).

Treatment: immediately after taking the drug inside, it is necessary to wash the stomach or induce artificial vomiting. The appointment of activated charcoal, symptomatic and supportive therapy is recommended. There is no specific antidote. Hemodialysis is not effective.

Interactions of Xyzal with other drugs

The study of the interaction of levocetirizine with other drugs has not been conducted. When studying the drug interaction of racemate cetirizine with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam, no clinically significant adverse interactions were identified.

With simultaneous administration with theophylline (400 mg / day), the total clearance of cetirizine is reduced by 16% (the kinetics of theophylline does not change).

In some cases, with the simultaneous use of levocetirizine with alcohol or drugs that depress the central nervous system, it is possible to increase their effect on the central nervous system, although it has not been proven that the racemate of cetirizine potentiates the effect of alcohol.

Special instructions for taking Xyzal

Caution is required when used simultaneously with alcohol (see "Interaction").

Influence on the ability to drive vehicles and control mechanisms. An objective assessment did not reliably indicate the effect of the drug on the ability to drive vehicles and control mechanisms when taken at the recommended dose. However, during the period of taking the drug, it is advisable to refrain from engaging in potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Storage conditions of the drug Xyzal

In a place protected from light, at a temperature not exceeding 30 ° C.

Shelf life of Xyzal

Xyzal belongs to the ATX classification:

R Respiratory system

R06 Antihistamines for systemic use

R06A Antihistamines for systemic use

R06AE Piperazine derivatives

Ksizal: instructions for use and reviews

Latin name: Xyzal

ATX code: R06AE09

Active substance: Levocetirizine (Levocetirizine)

Manufacturer: YUSB PHARMA S.A. (Belgium), UCB Pharma, S.p.A. (Italy), FARCHIM, S.A. (Switzerland)

Description and photo update: 12.08.2019

Ksizal is an antiallergic agent, a blocker of histamine H 1 receptors.

Release form and composition

Dosage forms of Xyzal:

  • Film-coated tablets: oval, almost white or white, with an embossed Y label on one side (7 or 10 pieces in blisters, in a carton pack 1 or 2 blisters);
  • Drops for oral administration: slightly opalescent colorless liquid (10 or 20 ml each in dark glass bottles with a dropper, 1 bottle in a cardboard box).

The active ingredient is levocetirizine dihydrochloride:

  • 1 tablet - 5 mg;
  • 1 ml drops - 5 mg.

Excipients:

  • Tablets: microcrystalline cellulose, lactose monohydrate, magnesium stearate, colloidal silicon dioxide;
  • Drops: sodium acetate, propylene glycol, glycerol 85%, sodium saccharinate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, acetic acid, purified water.

Additionally, as part of the film shell of tablets: Opadry Y-1-7000 (macrogol 400, titanium dioxide (E171), hypromellose).

Pharmacological properties

Pharmacodynamics

Levocetirizine - the active component of Xyzal - is the R-enantiomer of cetirizine, which is included in the category of competitive histamine antagonists and blocks H 1 -histamine receptors. This compound affects the histamine-dependent stage of an allergic nature, and also reduces vascular permeability, inhibits the migration of eosinophils, and limits the release of inflammatory mediators.

Levocetirizine prevents the occurrence and facilitates the course of allergic reactions, has an antipruritic and antiexudative effect. It has almost no antiserotonin and anticholinergic effects. In therapeutic doses, taking Xyzal does not lead to the development of a sedative effect.

Pharmacokinetics

Pharmacokinetic parameters of levocetirizine are characterized by a linear relationship. After oral administration, it is rapidly and almost completely absorbed from the gastrointestinal tract. Eating does not affect the completeness of absorption, but somewhat slows down its speed. The maximum content of levocetirizine in blood plasma is observed after 0.9 hours and is 270 ng / ml. Determination of the equilibrium concentration becomes possible 2 days after administration.

The degree of binding of levocetirizine to plasma proteins is 90%. The volume of distribution is 0.4 l/kg. The bioavailability of this compound reaches 100%.

Less than 14% of levocetirizine is metabolized in the liver, forming a metabolite with almost zero pharmacological activity. The half-life in adult patients is 7.9 ± 1.9 hours, and the total clearance is 0.63 ml / min / kg. Approximately 85.4% of the accepted dose of Xyzal is excreted in the urine, about 12.9% in the feces. In patients with renal insufficiency with CC less than 40 ml / min, the clearance of the drug is reduced. In patients on hemodialysis, the total clearance is reduced by 80%, which requires correction of the dosing regimen. Less than 10% of levocetirizine is excreted during a standard hemodialysis procedure lasting 4 hours.

Indications for use

According to the instructions, Xyzal is indicated for the symptomatic treatment of diseases and conditions of allergic origin:

  • Allergic rhinitis seasonal (intermittent) and year-round (persistent);
  • Pollinosis, or hay fever;
  • Allergic conjunctivitis with characteristic symptoms such as itching, nasal congestion and sneezing, rhinorrhea, conjunctival hyperemia, lacrimation;
  • Allergic dermatoses that occur with itching and rashes;
  • Urticaria, including chronic idiopathic urticaria;
  • Quincke's edema.

Contraindications

  • Terminal (final) stage of renal failure (with creatinine clearance (CC) less than 10 ml / min.);
  • The period of pregnancy and breastfeeding;
  • Individual hypersensitivity to the components of the drug.

The use of Xyzal tablets is contraindicated in patients with galactosemia or severe lactose intolerance, and in children under 6 years of age.

Drops Ksizal can not be used to treat children under the age of 2 years.

Instructions for use of Ksizal: method and dosage

The drug in the form of tablets and drops is taken orally on an empty stomach or with meals.

Tablets should be swallowed whole with plenty of water.

Ksizal drops can be diluted with a small amount of water immediately before taking.

Children from 2 to 6 years old should take 5 drops 2 times a day.

Patients with renal insufficiency and the elderly need to adjust the daily dose of Xyzal.

Recommended dosing of Xyzal for patients with renal insufficiency: mild (CC 50-79 ml / min.) - do not change the dose, moderate (CC 30-49 ml / min.) - the patient is prescribed 5 mg per day 1 time in 2 days; severe (CC less than 30 ml / min.) - 5 mg per day 1 time in 3 days.

The dosage regimen for patients with impaired liver function does not need to be corrected.

The duration of treatment depends on the clinical indications. With pollinosis, the drug should be taken for 1-6 weeks (on average), for chronic diseases (atopic dermatitis, year-round rhinitis) - 18 months.

Side effects

The use of Xyzal can cause side effects:

  • From the side of the cardiovascular system: very rarely - tachycardia;
  • From the nervous system: infrequently - fatigue, drowsiness and headache; rarely - general weakness; very rarely - agitation, aggression, convulsions, depression, visual impairment, hallucinations;
  • From the respiratory system: very rarely - shortness of breath (dyspnea);
  • From the side of metabolism: very rarely - weight gain;
  • From the digestive system: infrequently - dryness in the oral cavity; rarely - abdominal pain; very rarely - diarrhea, nausea, changes in liver function tests, hepatitis;
  • From the musculoskeletal system: very rarely - myalgia;
  • Allergic reactions: very rarely - rash, pruritus, urticaria, anaphylaxis, angioedema.

Overdose

Signs of an overdose of Xyzal are drowsiness (in adult patients) and a state of agitation and anxiety, followed by drowsiness (in children). After taking the drug in high doses, it is necessary to wash the stomach as soon as possible or induce artificial vomiting. After that, they take activated charcoal and prescribe symptomatic and supportive therapy. There is no specific antidote. The effectiveness of hemodiadesis is minimal.

special instructions

The use of Xyzal in recommended doses does not cause undesirable effects that affect the patient's ability to drive vehicles and mechanisms. Despite this, during the period of treatment, potentially hazardous activities should be avoided, the implementation of which requires concentration of attention and a high speed of psychomotor reactions.

Use during pregnancy and lactation

Adequate and well-controlled clinical studies on the safety of the use of Xyzal in pregnant women have not been conducted, so it is recommended to refrain from prescribing it during pregnancy. Levocetirizine passes into breast milk, so if it is necessary to take it during lactation, breastfeeding should be abandoned until the end of the course of treatment. Experimental animal studies have not found any direct and indirect adverse effects of levocetirizine on the developing fetus (including the postnatal period), the course of pregnancy and childbirth also proceeded within the normal range.

Use in the elderly

Since levocetirizine is excreted through the kidneys, when prescribing it to elderly patients, dose adjustment is necessary in accordance with the value of creatinine clearance.

drug interaction

Drug interactions of levocetirizine with other drugs have not been established.

Analogues

Xizal's analogues are: Glenset, Zenaro, Suprastinex, Caesera, Elzet, Aleron, Alerzin.

Terms and conditions of storage

Keep out of the reach of children:

  • Tablets: in a dry place at temperatures up to 25 ° C;
  • Drops: in a place protected from light at temperatures up to 30 ° C.

Shelf life: tablets - 4 years, drops - 3 years.

After opening the bottle, the drops are suitable for use within 3 months.

In this article, you can read the instructions for using the drug Xizal. Reviews of site visitors - consumers of this medicine, as well as opinions of doctors of specialists on the use of Xyzal in their practice are presented. A big request to actively add your reviews about the drug: did the medicine help or not help get rid of the disease, what complications and side effects were observed, perhaps not declared by the manufacturer in the annotation. Ksizal analogues in the presence of existing structural analogues. Use for the treatment of rhinitis, conjunctivitis, urticaria and other manifestations of allergies in adults, children, as well as during pregnancy and lactation. The composition and interaction of the drug with alcohol.

Xizal- a blocker of histamine H1 receptors, an enantiomer of cetirizine, belongs to the group of competitive histamine antagonists. The affinity for histamine H1 receptors in levocetirizine (the active substance of Xyzal) is 2 times higher than that of cetirizine.

Xyzal affects the histamine-dependent stage of allergic reactions, and also reduces the migration of eosinophils, reduces vascular permeability, and limits the release of inflammatory mediators. It prevents the development and facilitates the course of allergic reactions, has an anti-exudative, antipruritic effect, practically does not have an anticholinergic and antiserotonin effect. In therapeutic doses, it practically does not have a sedative effect.

Compound

Levocetirizine dihydrochloride + excipients.

Pharmacokinetics

The pharmacokinetic parameters of levocetirizine change linearly and practically do not differ from the pharmacokinetics of cetirizine. After oral administration, levocetirizine is rapidly absorbed from the gastrointestinal tract. Eating does not affect the degree of absorption, although its rate decreases. Bioavailability is 100%. The binding of levocetirizine to plasma proteins is 90%. Less than 14% is metabolized in the liver by N- and O-dealkylation (unlike other histamine H1 receptor blockers, which are metabolized in the liver with the participation of isoenzymes of the cytochrome P450 system) with the formation of a pharmacologically inactive metabolite. Due to the low metabolic rate and the lack of metabolic potential, the interaction of levocetirizine with other drugs is unlikely. About 85.4% of the dose is excreted unchanged by the kidneys by glomerular filtration and tubular secretion; about 12.9% is excreted through the intestines.

Indications

Symptomatic therapy of allergic diseases and conditions:

  • year-round (persistent) and seasonal (intermittent) allergic rhinitis and allergic conjunctivitis (itching, sneezing, rhinorrhea, lacrimation, conjunctival hyperemia, nasal congestion);
  • pollinosis (hay fever);
  • urticaria (including chronic idiopathic urticaria);
  • angioedema;
  • other allergic dermatoses, accompanied by itching and rashes.

Release form

Film-coated tablets 5 mg.

Drops for oral administration.

Instructions for use and dosing regimen

The drug is administered orally during a meal or on an empty stomach.

Tablets are taken with a small amount of water, without chewing.

Drops for oral administration are taken with a teaspoon. If necessary, the dose of the drug can be diluted in a small amount of water immediately before use.

Adults and children over 6 years: daily dose of 5 mg (1 tablet or 20 drops).

Side effect

  • headache;
  • fatigue;
  • drowsiness;
  • asthenia;
  • aggression;
  • excitation;
  • convulsions;
  • hallucinations;
  • depression;
  • visual impairment;
  • tachycardia;
  • dyspnea;
  • dry mouth;
  • abdominal pain;
  • nausea;
  • diarrhea;
  • hepatitis;
  • myalgia;
  • weight gain;
  • rash;
  • hives;
  • angioedema;
  • anaphylaxis.

Contraindications

  • terminal stage of renal failure (CC less than 10 ml / min);
  • children's age up to 6 years (for tablets);
  • children's age up to 2 years (for oral drops);
  • pregnancy;
  • hypersensitivity to the components of the drug, especially in patients with galactosemia or severe lactose intolerance (for tablets);
  • hypersensitivity to levocetirizine or piperazine derivatives.

Use during pregnancy and lactation

Adequate and strictly controlled clinical studies on the safety of the drug in pregnant women have not been conducted, so Xyzal should not be prescribed during pregnancy.

Levocetirizine is excreted in breast milk, therefore, if it is necessary to use the drug during lactation, breastfeeding should be discontinued at the time of administration.

In experimental studies on animals, no direct or indirect adverse effects of levocetirizine on the developing fetus (including in the postnatal period) were revealed, the course of pregnancy and childbirth also did not change.

Use in children

Contraindicated in children under 6 years of age (for tablets); in children under 2 years of age (for oral drops).

Children over 6 years: daily dose of 5 mg (1 tablet or 20 drops).

Children aged 2 to 6 years: 1.25 mg (5 drops) 2 times a day; daily dose - 2.5 mg (10 drops).

Use in elderly patients

Since Ksizal is excreted by the kidneys, when prescribing the drug to elderly patients, the dose should be adjusted depending on the size of the CC.

special instructions

The patient should be careful when taking the drug and the simultaneous use of alcohol.

Influence on the ability to drive vehicles and control mechanisms

An objective assessment of the ability to drive vehicles and work with mechanisms did not reliably reveal any adverse events when prescribing the drug at the recommended dose. However, during the period of treatment, it is advisable to refrain from engaging in potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

drug interaction

The study of the interaction of levocetirizine with other drugs has not been conducted.

When studying the drug interaction of racemate cetirizine with pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam, no clinically significant undesirable interaction was detected.

With simultaneous use with theophylline (400 mg per day), the total clearance of cetirizine is reduced by 16%, the pharmacokinetic parameters of theophylline do not change.

In some cases, with the simultaneous use of Xyzal with ethanol (alcohol) or drugs that have a depressant effect on the central nervous system, it is possible to increase their effect on the central nervous system, although it has been proven that the cetirizine racemate potentiates the effect of alcohol.

Analogues of the drug Ksizal

Structural analogues for the active substance:

  • Glenset;
  • Zenaro;
  • Zodak Express;
  • Levocetirizine;
  • Suprastinex;
  • Caeser;
  • Elzet.

Analogues for the therapeutic effect (remedies for the treatment of hay fever):

  • Allerfex;
  • Benarin;
  • Vibrolor;
  • Vibrocil;
  • Delufen;
  • Zincet;
  • Zyrtec;
  • Zodak;
  • Zodak Express;
  • Kestin;
  • Ketotifen;
  • Claridol;
  • Letizen;
  • Lotharen;
  • Nazarel;
  • Peritol;
  • Pipolfen;
  • Primalan;
  • Ruzam;
  • Syngulex;
  • Suprastin;
  • Suprastinex;
  • Tavegil;
  • Telfast;
  • Feksadin;
  • Fenkarol;
  • Cetrin;
  • Erius;
  • Erolyn.

In the absence of analogues of the drug for the active substance, you can follow the links below to the diseases that the corresponding drug helps with and see the available analogues for the therapeutic effect.

Xyzal is an antiallergic drug belonging to the group of H1-antihistamines.

Release form and composition

Ksizal is available in the form:

  • Oval-shaped tablets coated with a white film, each of which contains 5 mg of the active substance - levocetirizine dihydrochloride, the remaining components are: magnesium stearate, lactose monohydrate, MCC, colloidal silicon dioxide. The composition of the shell includes macrogol 400, titanium dioxide, hypromellose. Ksizal is sold in 7 or 10 tablets contained in cell packs, packed in cardboard boxes of 1 or 2 pieces;
  • Drops intended for oral administration, which are a colorless solution, 1 ml of which contains 5 mg of the active ingredient - levocetirizine dihydrochloride and auxiliary components in the form of: propyl parahydroxybenzoate, sodium saccharinate, propylene glycol, acetic acid, sodium acetate, glycerol 85%, methyl parahydroxybenzoate, purified water . Ksizal is sold in a dropper bottle with a dosage of 10 or 20 ml, in a cardboard box.

Indications for use of Ksizal

According to the instructions, Ksizal is prescribed for the treatment of the following allergic lesions and conditions:

  • pollinosis (hay fever);
  • Seasonal and year-round allergic rhinitis and conjunctivitis, expressed by sneezing, itching, lacrimation, conjunctival hyperemia, nasal congestion, rhinorrhea;
  • Quincke's edema;
  • Urticaria (including chronic idiopathic form);
  • Manifested by rashes and itching of allergic dermatoses.

Contraindications

The use of Ksizal, according to the instructions, is contraindicated in:

  • Severe form of renal failure;
  • Hypersensitivity to levocetirizine, other ingredients of the drug or piperazine derivatives;
  • Pregnancy, due to the lack of data on the safety of using Xyzal during this period;
  • Breastfeeding (the penetration of the drug into breast milk has been proven);
  • Children under 6 years old, for the tablet form of Ksizal, and up to 2 years old - in the treatment of drops;
  • Lactose intolerance or galactosemia (for tablets).

How to use Xyzal and dosage

The medication should be taken orally, at the same time as meals or on an empty stomach, without crushing or chewing, with water. When using drops, it is recommended to use a teaspoon; before taking, it is allowed to dilute the medicine with a small amount of water. According to the instructions for Xyzal, children over 6 years old and adults are prescribed 5 mg of the drug per day, which is equivalent to 1 tablet or 20 drops. Children aged 2-6 years are recommended 5 drops twice a day (2.5 mg per day - 10 drops).

The duration of therapy depends on the disease: for hay fever, Ksizal is recommended for 1 to 6 weeks, in the treatment of chronic lesions, tablets can be prescribed for up to six months, drops for up to 18 months. For elderly patients, as well as those suffering from pathologies of kidney activity, dose adjustment is necessary, depending on the magnitude of creatinine clearance (the drug can be prescribed once every 1-3 days).

Side effects of Xyzal

According to patients, when using Ksizal, the appearance of rapid fatigue, abdominal pain, drowsiness, headaches, dry mouth, and asthenia was sometimes noted. In rare cases, there may be: visual impairment, weight gain, diarrhea, nausea, hepatitis, myalgia, dyspnea, tachycardia, agitation, aggression, hallucinations, depression, convulsions, changes in liver function tests. Also, the use of Xyzal tablets and drops can provoke allergic reactions in the form of itching, urticaria, rash, anaphylaxis, angioedema.

An overdose of Ksizal is manifested in adults by drowsiness, and in children by agitation and anxiety, turning into drowsiness. In this condition, gastric lavage is prescribed, then maintenance therapy, the use of hemodialysis is not effective, there is no specific antidote.

special instructions

Do not use the drug simultaneously with alcoholic beverages and drugs that suppress the activity of the central nervous system, because of the risk of increasing their negative effects.

Ksizal's analogs

Xyzal's analogues, which have the same active ingredient as this drug, are Glentset, Levocetirizine-Teva, Suprastinex, Caesera, Elzet, Zenaro.

Medicines similar to Xizal in terms of mechanism of action include: Cetirizine Hexal, Zirtek, Alerza, Zetrinal, Letizen, Zodak, Cetirinax, Parlazin, Zincet, Cetrin,

Storage conditions and terms

Xyzal should be stored below 25°C, away from light sources. Shelf life - 3 years. The drug, produced in the form of drops, is suitable for use no more than 3 months after opening the vial.

@ 2022 wowway.ru - Diets and nutrition. Diagnostics and analyses. Medicines. Cholesterol. Atherosclerosis